Knowledge of the antigenic structure of foot-and-mouth disease virus (FMDV) has relevance in the development of diagnostic assays, in the evaluation of the antigenic variability and in the selection of appropriate vaccine strains. Antigenic sites have been investigated only in FMDVs of serotypes O, A and C, while it would be valuable to extend studies also to other serotypes. This paper reports the identification of antigenic sites involved in virus neutralization in the FMDV serotype Asia 1 by using a new panel of mAbs and their relation with sites described in other serotypes is discussed. Out of 24 mAbs raised against the FMDV serotype Asia 1, 10 neutralize viral infectivity and were used to select FMDV mutants resistant to neutralization. On the basis of their reactivity profile with virus mutants, the 10 neutralizing mAbs were clustered in four groups corresponding to four independent antigenic sites. By comparing the amino acid sequence of the parental virus and of virus mutants, the amino acids crucial for the four sites were mapped at the following positions: VP1 140-142, VP2 67-79, VP3 58/59 and VP3 218. Three of the four neutralizing sites identified and mapped on FMDV serotype Asia 1 correspond structurally and functionally to analogous sites described in FMDV serotypes O, A and C, enforcing the evidence that these are dominant antigenic sites in the FMDV structure. The fourth site, located at the C terminus of VP3, is a new independent site, described for the first time in FMDV.
INTRODUCTION
Foot-and-mouth disease (FMD) viruses constitute one genus (Aphthovirus) in the family Picornaviridae, but are classified into seven serotypes (O, A, C, Asia 1, SAT1, SAT2 and SAT3), each of which shows considerable intra-type variation. Infection or vaccination with one serotype does not confer protection against other serotypes and may only be partially effective against some subtypes within the same serotype. This antigenic variation leads to continuing difficulties in controlling the disease.
The viral icosahedral capsid is composed of 60 copies of each structural protein VP1, VP2, VP3 and VP4. Studies on the antigenicity of FMDV, complemented with crystallographic analysis of the three-dimensional structure of the virus and of virus-antibody complexes, have improved understanding of the interaction between virus and the host immune system, including the mechanism of virus escape from neutralization, which is also responsible for the high antigenic diversification of FMDVs.
The identification of antigenic sites in FMDV has mainly relied on the use of mAbs, and partly also on the evaluation of immunogenicity and antigenicity of viral peptides.
However, synthetic peptides only allow the study and characterization of linear epitopes, while the use of mAbs, combined with detection of amino acid substitutions in virus mutants resistant to neutralizing mAb, allows the identification of any kind of antigenic sites, either linear or dependent on conformation, provided that they are involved in virus neutralization processes.
Using this approach, antigenic sites have been identified and mapped on FMDVs type O (Xie et al., 1987; Pfaff et al., 1988; Barnett et al., 1989; Kitson et al.,1990; Aktas & Samuel, 2000) , type A (Thomas et al., 1988; Baxt et al., 1989; Bolwell et al., 1989 , Mahapatra et al., 2011 and type C (Mateu et al., 1990; Lea et al., 1994) . Results of these studies provided evidence that, in addition to the continuous epitope termed site 1 or site A, located within the large and flexible G-H loop of VP1 and initially considered the main if not the single immunodominant site, other epitopes, not found in continuous sequences but dependent on capsid conformation, also exist in all the three serotypes investigated (Mateu, 1995) . Specific amino acid residues in the three structural proteins VP1-3 have been identified as crucial elements for the site antigenicity and these residues are more frequently located within loops exposed on the virus surface.
These studies were conducted on historical isolates of FMDV serotypes O, A, C which are extinct from the field. Furthermore, it would be useful to extend investigations also to other serotypes of FMDV, either to improve basic knowledge on the virus structure and antigenicity, and for the benefits that this knowledge may reflect on the selection of appropriate strategies for the disease control. Further knowledge on the antigenic structure and the availability of well characterized mAbs have useful applications also in the design of functional diagnostic assays, in studies on the antigenic evolution of FMDVs and for vaccine matching. In this study we describe the identification and characterization of neutralizing sites on the FMDV serotype Asia 1 by a new panel of mAbs. Four independent sites have been identified, three of which, located on VP1, VP2 and VP3, respectively, correspond to sites previously demonstrated in FMDV serotypes O, A and C, while a fourth one is a new site described for the first time in FMDV.
RESULTS

Characterization of mAbs
Twenty-four mAbs were raised against FMDV serotype Asia 1, strain Nepal 29/97. A preliminary characterization was achieved by analysing the immunoglobulin class, the capability to neutralize viral infectivity, the reactivity with separated, denatured viral proteins (immunoblotting), the level of inter-type cross-reactivity with FMDV strains representative of the other six heterologous serotypes and the intra-type cross-reactivity with 24 field isolates of serotype Asia 1 collected from 1973 to 2009 (Table 1) .
Based on the results of the virus neutralization test, mAbs were divided into two main categories: one including 10 mAbs that neutralize virus infectivity, another composed by 14 non-neutralizing mAbs.
Of the neutralizing mAbs, three (4E10, 4F10 and 5C12) recognized the denatured VP1 in immunoblotting ( Fig. 1 ) and trypsin treatment of the virus prevented this reactivity (data not shown), suggesting that their target site should correspond to the linear amino acid sequence containing the trypsin-sensitive site on the flexible G-H loop of VP1. Interestingly, these three mAbs showed a high degree of cross-reactivity with the heterologous serotype SAT 3, as evidenced by their reactivity in ELISA (Table 1) as well as by their capability to neutralize the SAT 3 serotype with the same efficiency as the homologous serotype (data not shown). The other seven neutralizing mAbs reacted as serotype-specific and negative in immunoblotting; the incapability to recognize any isolated and denatured viral proteins is indicative of the conformation nature of the target epitopes.
The profile of reactivity with the 24 field isolates provided evidence of different extents of antigenic variability: none of the neutralizing mAbs recognized all the isolates, approximately 50 % mAbs detected the majority of isolates, whilst the remaining mAbs reacted almost exclusively with the homologous strain. However, one isolate, Cambodia 3/ 93, was not recognized by any neutralizing mAb, suggesting a significant antigenic divergence of this isolate.
Among the non-neutralizing mAbs, two (4G6 and 3D8) were serotype-specific, while other 12 mAbs showed different patterns of cross-reactivity with heterologous serotypes. The most common pattern, shown by four mAbs (3G3, 2A4, 3B6 and 5H5), was the reactivity with the four FMDV serotypes Asia 1, O, A and C; two mAbs reacted with all the seven serotypes (4G2 and 3H12), while another one (5F10) recognized all serotypes but SAT 1. Thirteen out of the 14 non-neutralizing mAbs were negative in immunoblotting, only one mAb (5F10) identified a linear epitope in VP2 (Fig. 1) , which was susceptible to cleavage by trypsin treatment (data not shown). With one exception, non-neutralizing mAbs displayed a broad reactivity with the 24 field isolates of serotype Asia 1 analysed. The antigenic stability of the relevant epitopes was expected, particularly for those conserved among different serotypes.
mAb neutralization-resistant mutants (MARmutants)
The selection, characterization and sequencing of viral mutants resistant to neutralization by each of the neutralizing mAbs was the approach adopted to identify and map the relevant target sites. From one to nine MARmutants were independently selected for each mAb by serial passages of the parental virus in the presence of high concentration of mAb. Mutants were analysed by both ELISA and virus neutralization test (VNT) against the 10 neutralizing mAbs, in order to detect reciprocal relationships on the basis of similar patterns of reactivity.
The antigenic profile of MAR-mutants determined by ELISA (Table 2 ) enabled clustering of mAbs in four groups that substantially identify four independent sites: in general, mutations in one site did not affect the reactivity of the other sites.
In particular, the MAR-mutants selected with mAbs 5C12, 4E10 and 4F10 (first group, reacting with VP1) showed homogeneous profiles: mutations induced in any escape mutant annulled the reaction of the three mAbs, without affecting the binding of the other seven mAbs. Three additional mAbs, 5E10, 3C6 and 1F10, formed a second homogeneous group: in fact, the 13 mutants selected with any of the three mAbs lost reactivity with all of them. Following the same interpretative criterion, mAbs 2C3, 2G1 and 4D8 formed a third group. A structural relationship between sites identified by mAbs of the second and the third group was evident, since variations in one site partially altered the reactivity of the other. Another site was defined by the unique mAb 5G4 (fourth group): it is clearly distinct in that the five mutants selected with this antibody were still recognized by all the other mAbs. *Reciprocal of saturating dilution of hybridoma supernatant; +same reactivity as with the homologous virus type; (+) reduced signal with respect to the homologous virus type; -/+ traces of reactivity; -negative.
Reciprocal of end-point neutralizing dilution of concentrated hybridoma supernatants. # Reactivity with field isolates is presented as numbers corresponding to percentage of reactivity related to the homologous virus; the intensity of the cells background is proportional to the intensity of the reaction. FMDV antigenic sites, serotype Asia 1
In order to evaluate the correlation between ELISA binding and neutralization pattern, one or two representative mutants for each mAb were also tested for the susceptibility to neutralization; the neutralization titres of the mAbs towards the parent virus and the mutant viruses were compared; it was arbitrarily assumed that differences in titres higher than 2 log 10 indicate resistance, differences between 1 and 2 log 10 indicate partial resistance and lower than 1 log 10 are indicative of susceptibility.
Results of these cross-neutralization assays (Table 3) fully confirmed the findings obtained by ELISA, providing further evidence of the four distinct sites, with a partial relationship between sites identified by mAbs of groups two and three.
Mapping of neutralizing sites
The sequence of the capsid coding region of some mutants was determined and compared to the parental sequence: this enabled detection of the amino acid substitutions responsible for the antigenic variations and mapping of the neutralizing sites, with identification of the secondary structural element involved (Tables 2 and 4 ).
Most mutants selected with mAbs of the first group showed a unique substitution at residue 142 of VP1, while one mutant exhibited two substitutions at residues 140 and 141 of VP1; these positions flank the conserved RGD motif and are included within the flexible G-H loop of VP1.
The site identified by mAbs of the third group involves multiple amino acid positions in the B-C loop of VP2: namely residues 67, 72, 74, 77 and 79. Two further changes at aa 48 and 207 of VP1, probably not related to the site, were found in one MAR-mutant.
The site recognized by mAbs of the second group maps at the aa positions 58 and 59 of VP3, located within the secondary structural element B-B knob. Additional changes sporadically found in VP3 (positions 64 and 103) were not considered as related to this site. However, further mutations at aa 67, 72 or 77 of VP2 were also detected in all mutants. These changes, also found in MAR-mutants selected with mAbs of the previous group, can justify the partially altered reactivity of those mAbs, confirming the structural relationship between these two sites, as shown by ELISA and VNT reactivity profile of the MAR-mutants.
The site identified by the unique mAb 5G4 (fourth group) has a critical aa at position 218 of VP3-carboxyl end.
Mutants selected with different mAbs defining the same site showed amino acid changes at the same or contiguous residues and in some mutants up to three simultaneous substitutions within the identified site were recorded; in addition, the same residue may be replaced by different amino acids with similar effects on the reactivity profile.
Amino acid positions responsible for antigenic changes in MAR-mutants were projected onto a three-dimensionalpentameric structure of a FMDV reduced O BFS.
As shown in Fig. 2(a) and (b), polarization of all the positions toward the external face of the pentamer was predicted, as expected for sites involved in neutralization.
Residues associated with the sites identified by mAbs of the second (VP3 58 and 59) and the third (VP2 67, 72, 74, 77 and 79) group are located at opposite sides of the protomeric structure (Fig. 2c) , near to the threefold axes of symmetry. However, the residues in VP2 and VP3 from adjacent protomers lie close to each other in the pentameric subunit (Fig. 2a) , corroborating the existence of a structural relationship between antigenic sites target of these two mAbs groups.
DISCUSSION
The objective of the present study was the identification and mapping of antigenic sites of the FMDV serotype Asia 1 by a new panel of mAbs, with focus on the sites involved in virus neutralization; results provided a better understanding of the antigenic structure of FMDV and allowed studying of the relationships with antigenic sites previously described in other FMDV serotypes, more extensively studied.
The evidence of different antigenic sites in the serotype Asia 1 was shown in previous studies by using mAbs (Sanyal et al., 1997; . The mAbs provided evidence of some antigenic variability among field isolates (Sanyal et al., 1997 (Sanyal et al., , 2003 , but mapping of the relevant sites was only attempted on the basis of the correspondence observed between mAbsprofiling and variations in the amino acid sequence of few isolates . The characterization of our The intensity of the cells shade is proportional to the intensity of the reaction of MAR-mutants with mAbs.
*In parentheses amino acid substitutions not considered crucial for site conformation.
FMDV antigenic sites, serotype Asia 1 new panel of mAbs, combined with sequencing of MARmutants, enabled the identification and mapping of four independent neutralizing sites, all clearly exposed on the external surface of the virion. Interestingly, three of the sites detected in the serotype Asia 1 correspond structurally and functionally to analogous antigenic sites described in FMDV serotypes O, A and C. Fig. 3 shows the location of critical amino acids for each neutralizing site and their correspondence between the four FMDV serotypes.
In order to harmonise the nomenclature of the antigenic sites among the different FMDV serotypes and therefore Numbers in cells express differences in VNT titres (log 10 ) to the parental and mutants viruses; black cells: differences .2 log 10 indicate resistance to neutralization; grey cells: differences between 1 and 2 log 10 indicate partial resistance; white cells: differences ,1 log 10 indicate sensitivity to neutralization. facilitate the interpretation, we adopted the same nomenclature assigned to the antigenic sites previously identified in the FMDV serotype O.
Accordingly, mAbs of the first group identify antigenic site 1 that was extensively described in the other three serotypes. This site is located within the surface exposed G-H loop of VP1, which contains a trypsin cleavage site and the highly conserved RGD (Arg-Gly-Asp) amino acid triplet, corresponding to the presumed site of cell attachment Mason et al., 1994) . Previous studies with different FMDV serotypes showed that several residues in the sequential segment 138-154 of the capsid protein are involved in determining site 1 antigenicity. Substitutions detected either in MAR-mutants, or in field variants occur in residues flanking both sides of the RGD motif (Stave et al., 1988; Bolwell et al., 1989; Mateu et al., 1990; Marquard & Freiberg, 2000; Mahapatra et al., 2011) . Consistently, also in the FMDV serotype Asia 1 the positions 140-142, which were found substituted in MAR-mutants, precede the RGD motif. The G-H loop is easily accessible on the virus surface and is characterized by high variability (Domingo et al., 1990) . The antigenic diversity in this region relies on its flexibility, as indicated by the disorder at G-H loop observed in crystal structures of both serotypes O (Acharya et al., 1989) and C (Lea et al., 1994) . In fact a flexible loop can accept different amino acid sequences, while preserving a functional capsid structure.
In spite of this concept, and in contrast with the sequence variability observed in some field isolates of serotype Asia 1 in the corresponding region , the spectrum of reactivity of our three mAbs directed to site 1 showed a substantial level of conservation among the field isolates tested. Furthermore, unexpectedly, the three of them also bound and neutralized the FMDV serotype SAT 3; the molecular basis that may explain cross-reactivity at this level should be further investigated.
It has been reported that VP1 C terminus (aa sequence 200-213) contributes to the formation of a discontinuous site together with site 1 in the FMDV serotype O (Xie et al., 1987; Parry et al., 1989) , but it may also behave as a topologically independent site in both serotypes O (site 5, Aktas & Samuel, 2000) and C (site C, Mateu et al., 1990) . Similarly, both situations have been observed in different strains of serotype A (Baxt et al., 1989; Thomas et al., 1988) . VP1 C terminus was described as a trypsin-sensitive, linear epitope of minor importance, given the weak neutralizing capability of mAbs towards it (Mateu et al., 1990 , Thomas et al., 1988 , their failure to compete with sera from convalescent animals (Thomas et al., 1988) and the poor capacity of VP1 C terminus to generate protecting antibodies (Melonen & Barteling, 1986) . Our mAbs panel does not provide evidence of antigenicity of VP1 C terminus in the FMDV serotype Asia 1; however, a substitution at residue 207 was detected in one MARmutant selected with mAbs of group III; this change is probably not related to the site target of this group of mAbs, but rather indicates the occurrence of variability in the VP1 C terminus region.
The mAbs of the second group map at positions 58/59 of VP3, located within the B-B knob structural element. The same antigenic site was found also in FMDV serotypes O (site 4), A (described as part of Ag-site III) and C (site D3). While the unique residue 58 was found crucial for this site in the serotypes O and C (Kitson et al., 1990; Lea et al., 1994) , in the serotype A several contiguous or close residues, namely 58-61, 69/70 and in addition two more distant positions, 139 and 195, seem to be part of this site (Thomas et al., 1988) . Two mAbs that bind to site 4 in the serotype Asia 1 (mAbs 1F10 and 3C6) displayed a wider intra-typic reactivity in contrast to the third one (mAb Fig. 3 . Mapping of amino acids positions critical for sites involved in neutralization on FMDV structural proteins and correspondence between antigenic sites described in different FMDV types. 5F10); for the antigenic variability of this site the aa position VP3 58, that is mutated in the 5E10 MAR-mutant, is likely to be more crucial than position 59.
The mAbs of the third group identify a site composed by several critical amino acids in the structural protein VP2, ranging from position 67 to 79. The multiple simultaneous substitutions found in most MAR-mutants selected with these mAbs support the assumption that the identified residues are all part of the same dominant antigenic domain. Interestingly, the same or contiguous residues were found crucial for the conformation of the analogous site in FMDV serotypes O (site 2, Kitson et al., 1990; Aktas & Samuel, 2000) , A (Ag-site III, Thomas et al.,1988) and C (site D2, Lea et al., 1994) . All the concerned residues lie in the exposed B-C loop of VP2. Frequent amino acids substitutions were demonstrated in this region in field isolates of serotype Asia 1 , indicating its susceptibility to variation. Consistently, our three mAbs to site 2 did not recognize most of the field isolates examined.
The profile of reactivity and the amino acids replacements of the MAR-mutants obtained with mAbs against sites 2 and 4 suggested a structural relationship between these two sites in serotype Asia 1. Similar findings were observed also in previous studies: in fact, in serotype A mutants induced with mAbs against the two sites showed a certain level of reciprocal cross-neutralization (Thomas et al., 1988) , while in serotype C both sites are considered parts of a unique complex antigenic site (Lea et al., 1994) . Furthermore, in the three-dimensional structure of the capsid, residues involved in formation of the two sites lie close to each other on the surface of the virion, around the threefold axes of symmetry ( Fig. 2 ; Kitson et al., 1990; Lea et al., 1994) .
The detection of equivalent antigenic domains in four different FMDV serotypes, detected through independent studies, enforces the evidence that these are dominant antigenic sites in the FMDV capsid structure. However, there are further conformational sites, implicated in neutralization processes, each described only in one FMDV serotype.
In the FMDV serotype A, a site of minor importance was found at position 169 (Baxt et al., 1989) and 173 (Thomas et al., 1988 ) of VP1; in serotype O the so called site 3 was mapped at the aa residues 43-45 and 48 of VP1 Kitson et al., 1990) . It was supposed that these two sites could be related to each other, as residues involved are located within two different loops (H-I and B-C loops, respectively) of VP1 lying adjacent on the virus surface. We did not find these positions as part of an antigenic site in the serotype Asia 1; however, one mutant obtained with site 2 mAbs presented, in addition to changes related to site 2, a substitution in position 48 of VP1. This substitution could be the result of one random mutation in a region that is probably subjected to variability also in serotype Asia 1.
A further position in VP1, mapping at residue 193, was recognized as another neutralizing site, named D1, only in serotype C (Lea et al., 1994) .
Our fourth group of mAbs specific for the FMDV serotype Asia 1, that includes the sole mAb 5G4 was mapped at position 218 of VP3; this mAb identifies a new site, here called site 5, that is reported for the first time in FMDV antigenic structure. The absence of reactivity of most of the 24 FMDV isolates of serotype Asia 1 with mAb 5G4 indicate that the target epitope is subjected to variability, in accordance with the frequent substitution rate detected in position VP3-218 by sequencing field isolates .
Further sites not involved in neutralization were detected by the group of 14 non-neutralizing mAbs, reacting with all Asia 1 field isolates and presenting different degrees of even inter-types cross-reactivity. One of these mAbs (5F10) recognizes a linear epitope in VP2, as proven by its profile of reactivity in immunoblotting; the epitope is susceptible to trypsin cleavage and is common to at least six serotypes. mAbs with analogous reactivity were independently selected by us and other authors from mice immunized with either FMDV serotype O, C, SAT 1 or Asia 1. The epitope target of these antibodies resides at the intertypically conserved N terminus of VP2, as demonstrated by the reactivity profile with synthetic peptides (Freiberg et al., 2001 and personal communication) . The remaining 13 non-neutralizing mAbs recognized conformational epitopes, indistinguishable from each other except for different patterns of inter-types crossreactivity.
Also non-neutralizing mAbs may have a potential value for the development of diagnostic assays, but they are more difficult to characterize than neutralizing mAbs. Therefore, there is a requirement to investigate alternative methods and strategies for their characterization.
In conclusion, our results have improved the understanding of the antigenic structure of FMDV, through the description of a new site involved in viral neutralization and enforcing the evidence of the immunodominant character of three antigenic sites detected in four different serotypes. These data may have useful application in diagnostic and epidemiological investigations, as mAbs directed against conserved epitopes provide universal reagents for FMDV detection systems, while mAbs against known variable sites readily allow the identification of field antigenic variants and represent strategic tools for vaccine-matching studies.
METHODS
Viruses. FMDV isolates used in this study were received from the World Reference Laboratory for FMD, Pirbright, UK; they are listed in Table 1 . Viruses were propagated in IBRS-2 cells monolayers and harvested when cytopathic effect (CPE) was maximum. The strain used for mice immunization and immunoblotting was preliminarily inactivated with binary ethylenemine and purified by ultracentrifugation through a 25 % (w/w) sucrose cushion. characterized by moderate antigenic and genomic variability, in fact all isolates are classified in a unique topotype. The strain used for mAbs production was selected as a representative of a series of genomically closely related isolates that occurred during the decade 1995-2005, and was preferred because more recent than the reference vaccine strain Asia 1 Shamir/89. Cell fusion and cloning of positive hybridomas were performed following procedures standardized in our laboratory (Brocchi et al., 1993) . Selection was based on results of a trapping ELISA against the homologous virus strain.
Isotype of the mAbs was determined using a commercial ELISA (Boehringer Mannheim isotyping kit).
Trapping ELISA. The assay used for mAbs titration and for the evaluation of their intra-and inter-types reactivity was a trapping ELISA (Samuel et al., 1991) . Essentially, each mAb was reacted with pre-titrated concentrations of viruses (supernatant of infected cells) that had been trapped using a rabbit immune serum raised against FMDV Asia 1. Titres of mAbs were expressed as the reciprocal of the saturating dilution, while the reactivity of mutants and field isolates with each mAb, used at the double saturating concentration, was expressed as a percentage of the corresponding reaction with the parental strain, assumed to be 100 %.
VNT. VNT was carried out in microplates against 100 TCID 50 of the homologous FMDV Asia 1 or of the mAb neutralization-resistant mutants, using IBRS-2 cell cultures. The final dilution required to neutralize 50 % of the inoculated cultures was calculated.
MAR-mutants. The selection of mutants resistant to neutralization by mAbs was carried out as described previously (Borrego et al. 2002) . Briefly, samples (50 ml) of serial tenfold dilutions of the parental FMDV, strain Asia 1 Nepal 29/97, 10 6.5 TCID 50 ml
21
, were mixed with 50 ml of mAbs at two fixed concentrations (20 and 100 mg ml 21 ) in wells of microplates. Then, a 100 ml volume of IBRS-2 cells at 10 5 cells ml 21 in growth medium was added to each well. After incubation for 2-3 days at 37 uC, 5-10 wells for each mAb showing CPE at the highest dilutions of virus were subcultured twice in 24-wells plates in the presence of an high mAb concentration (100-200 mg ml
). For three mAbs (2C3, 3C6 and 1F10) no mutant could be selected under these conditions; in these cases concentration of the selecting mAbs in the lower range of 2-10 mg ml 21 were adopted initially, followed by gradually increasing concentrations for subsequent virus passages.
A fourth passage without mAb was performed and presumptive mutants were harvested when CPE was evident (24-48 h postinfection). After ensuring the lack of reactivity against the selecting mAb by trapping ELISA, several MAR-mutants for each mAb were amplified and analysed further.
Immunoblotting. Hybridoma supernatants were assayed against the purified homologous FMDV, resolved by SDS-PAGE 10 or 12 % and transferred to nitrocellulose filters, following standard procedures (Towbin et al., 1979) . Membranes were blocked with 2 % BSA in PBS containing 0.05 % Tween 20 and incubated for 1 h with hybridoma supernatants. Following several washings, binding of mAbs was detected by home-made alkaline phosphatase-conjugated anti-mouse immunoglobulins and the chromogenic substrate BCIP/NBT (Harlow & Lane, 1988) .
Sequencing. RNA extracted from the supernatant of infected cultures, using a commercial kit (Qiagen RNeasy Mini kit; Qiagen) was used as the template for RT-PCR. Reverse transcription was carried out using AMV reverse transcriptase with a hexanucleotide mixture of all possible sequences ('Random' primer; Roche). The cDNA produced was used as the template for PCR amplification of the region encoding the structural proteins using the primers described in Table S1 (available in JGV Online). The polyprotein P1 was amplified in five fragments that included also some flanking nucleotides from both the 59 non-translated region and protein 2A. Sequencing of PCR fragments and sequence analysis were carried out using an ABI 310 Automatic Sequencer and LaserGene software (DNASTAR Inc.). The sequence of the P1 of the parental strain (FMDV Asia 1 Nepal 29/97) has been submitted to the GenBank database (accession number EF134952).
The X-ray coordinates of a pentamer of FMDV reduced O BFS (Logan et al., 1993) were employed to visualize the position of the critical capsid amino acids residues as identified by sequencing the Asia 1 MAR-mutant viruses. The PyMol Molecular Graphics System v1.2r0 (DeLano Scientific LLC) was used to generate the pictures.
